Anti-pre-BCR antagonists and methods
This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.
1. A method comprising:
administering to a subject having B cell precursor acute lymphoblastic leukemia (BCP-ALL) a therapeutic composition in an amount effective to ameliorate at least one symptom or clinical sign of BCP-ALL, the therapeutic composition comprising an antibody comprising the amino acid sequences of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13.
2. The method of claim 1 , wherein the antibody is humanized.
3. The method of claim 1 , wherein the therapeutic composition further comprises a toxin conjugated to the antibody.
4. The method of claim 1 , wherein the antibody light chain comprises the amino acid sequences of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.
5. The method of claim 1 , wherein the antibody heavy chain comprises the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13.
6. The method of claim 4 , wherein the antibody light chain comprises SEQ ID NO:6.
7. The method of claim 5 , wherein the antibody heavy chain comprises SEQ ID NO:10.